G Hess1, J Moecks, D Zdunek. 1. Roche Diagnostics GmbH, Sandhofer Str. 116, 68305 Mannheim, Germany. georg.hess@roche.com
Abstract
BACKGROUND: Natriuretic peptides represent a novel diagnostic tool in the assessment of cardiac dysfunction. METHODS: A total of 473 consecutive referred patients presenting to 18 cardiologists for the assessment of their cardiac state were recruited for the study. Patients received a medical history, a physical examination an electrocardiogram and an echocardiogram where left ventricular ejection fraction was recorded. RESULTS: NT-proBNP was found to correlate with left ventricular ejection fraction (LVEF), level of symptoms (NYHA classification), history of angina pectoris (AP) and myocardial infarction (AMI). Atrial fibrillation (AF) and thyroid dysfunction as well as renal impairment were shown to influence NT-proBNP levels. CONCLUSION: The study supports the hypothesis that NT-proBNP determination contributes to the assessment of patients presenting to cardiologists.
BACKGROUND: Natriuretic peptides represent a novel diagnostic tool in the assessment of cardiac dysfunction. METHODS: A total of 473 consecutive referred patients presenting to 18 cardiologists for the assessment of their cardiac state were recruited for the study. Patients received a medical history, a physical examination an electrocardiogram and an echocardiogram where left ventricular ejection fraction was recorded. RESULTS: NT-proBNP was found to correlate with left ventricular ejection fraction (LVEF), level of symptoms (NYHA classification), history of angina pectoris (AP) and myocardial infarction (AMI). Atrial fibrillation (AF) and thyroid dysfunction as well as renal impairment were shown to influence NT-proBNP levels. CONCLUSION: The study supports the hypothesis that NT-proBNP determination contributes to the assessment of patients presenting to cardiologists.
Authors: Michael H Olsen; Kristian Wachtell; Christian Tuxen; Eigil Fossum; Lia E Bang; Christian Hall; Hans Ibsen; Jens Rokkedal; Richard B Devereux; Per Hildebrandt Journal: J Hypertens Date: 2004-08 Impact factor: 4.844
Authors: Jennifer Franke; Lutz Frankenstein; Dieter Schellberg; Amer Bajrovic; Jan Sebastian Wolter; Philipp Ehlermann; Andreas O Doesch; Manfred Nelles; Hugo A Katus; Christian Zugck Journal: Clin Res Cardiol Date: 2011-07-16 Impact factor: 5.460
Authors: Frank Peters-Klimm; Cornelia U Kunz; Gunter Laux; Joachim Szecsenyi; Thomas Müller-Tasch Journal: Health Qual Life Outcomes Date: 2010-09-13 Impact factor: 3.186
Authors: Nicole Lossnitzer; Beate Wild; Jobst-Hendrik Schultz; Lutz Frankenstein; Markus Haass; Bernhard Rauch; Bernd Löwe; Hugo Katus; Wolfgang Herzog Journal: Int J Behav Med Date: 2014-12
Authors: Frank Peters-Klimm; Stephen Campbell; Thomas Müller-Tasch; Dieter Schellberg; Goetz Gelbrich; Wolfgang Herzog; Joachim Szecsenyi Journal: Trials Date: 2009-08-13 Impact factor: 2.279